The Experts below are selected from a list of 272322 Experts worldwide ranked by ideXlab platform
Michael J Rybak - One of the best experts on this subject based on the ideXlab platform.
-
therapeutic monitoring of vancomycin for serious methicillin resistant staphylococcus aureus infections a revised consensus guideline and review by the american society of health system pharmacists the Infectious Diseases society of america the pediatric Infectious Diseases society and the society of Infectious Diseases pharmacists
Clinical Infectious Diseases, 2020Co-Authors: John S Bradley, Michael J Rybak, Thomas P Lodise, Donald P Levine, Catherine LiuAbstract:Recent clinical data on vancomycin pharmacokinetics and pharmacodynamics suggest a reevaluation of current dosing and monitoring recommendations. The previous 2009 vancomycin consensus guidelines recommend trough monitoring as a surrogate marker for the target area under the curve over 24 hours to minimum inhibitory concentration (AUC/MIC). However, recent data suggest that trough monitoring is associated with higher nephrotoxicity. This document is an executive summary of the new vancomycin consensus guidelines for vancomycin dosing and monitoring. It was developed by the American Society of Health-System Pharmacists, the Infectious Diseases Society of America, the Pediatric Infectious Diseases Society, and the Society of Infectious Diseases Pharmacists vancomycin consensus guidelines committee. These consensus guidelines recommend an AUC/MIC ratio of 400-600 mg*hour/L (assuming a broth microdilution MIC of 1 mg/L) to achieve clinical efficacy and ensure safety for patients being treated for serious methicillin-resistant Staphylococcus aureus infections.
-
recommendations for training and certification for pharmacists practicing mentoring and educating in Infectious Diseases pharmacotherapy joint opinion of the society of Infectious Diseases pharmacists and the Infectious Diseases practice and research network of the american college of clinical pharmacy
Pharmacotherapy, 2009Co-Authors: Erika J Ernst, Michael E Klepser, John A Bosso, Michael J Rybak, Elizabeth D Hermsen, Marisel Segarranewnham, Richard H DrewAbstract:Recently created guidelines for the development of institutional antimicrobial stewardship programs recommend that a pharmacist with Infectious Diseases training be included as a core member of the antimicrobial stewardship team. However, training and certification requirements for Infectious Diseases-trained clinical pharmacists have not been established. Although pharmacists have nurtured their interest in Infectious Diseases by self-directed learning or on-the-job experiences, this mode of training is not considered feasible or sufficient for reliable training of future clinical specialists in Infectious Diseases. This document, therefore, is forward looking and provides overarching recommendations for future training and certification of pharmacists practicing, mentoring, and educating in Infectious Diseases pharmacotherapy, with the recognition that full implementation may take several years. We recommend that future pharmacists wishing to obtain a clinical position as an Infectious Diseases-trained pharmacist should complete a postgraduate year (PGY) 1 residency and a PGY2 residency in Infectious Diseases, that practitioners become board-certified pharmacotherapy specialists, that a certification examination in Infectious Diseases be developed, that practitioners maintain a portfolio of educational experiences to maintain qualifications, that current nonaccredited training programs seek accreditation, and that employers and academicians recognize the desirability of these qualifications in hiring decisions.
Anthony S Fauci - One of the best experts on this subject based on the ideXlab platform.
-
emerging Infectious Diseases threats to human health and global stability
PLOS Pathogens, 2013Co-Authors: David M. Morens, Anthony S FauciAbstract:The inevitable, but unpredictable, appearance of new Infectious Diseases has been recognized for millennia, well before the discovery of causative Infectious agents. Today, however, despite extraordinary advances in development of countermeasures (diagnostics, therapeutics, and vaccines), the ease of world travel and increased global interdependence have added layers of complexity to containing these Infectious Diseases that affect not only the health but the economic stability of societies. HIV/AIDS, severe acute respiratory syndrome (SARS), and the most recent 2009 pandemic H1N1 influenza are only a few of many examples of emerging Infectious Diseases in the modern world [1]; each of these Diseases has caused global societal and economic impact related to unexpected illnesses and deaths, as well as interference with travel, business, and many normal life activities. Other emerging infections are less catastrophic than these examples; however, they nonetheless may take a significant human toll as well as cause public fear, economic loss, and other adverse outcomes.
-
the perpetual challenge of Infectious Diseases
The New England Journal of Medicine, 2012Co-Authors: Anthony S Fauci, David M. MorensAbstract:During the past 200 years, our understanding of Infectious Diseases has radically evolved from the identification of microbes, to defining their genetic structure, to the development of focused antimicrobial therapies, to the realization of vector biology. This article highlights the tremendous advances that have been made in the field.
-
emerging Infectious Diseases a 10 year perspective from the national institute of allergy and Infectious Diseases
Emerging Infectious Diseases, 2005Co-Authors: Anthony S Fauci, Nancy A Touchette, Gregory K. FolkersAbstract:Although optimists once imagined that serious Infectious disease threats would by now be conquered, newly emerging (e.g., severe acute respiratory syndrome [SARS]), reemerging (e.g., West Nile virus), and even deliberately disseminated Infectious Diseases (e.g., anthrax bioterrorism) continue to appear throughout the world. Over the past decade, the global effort to identify and characterize Infectious agents, decipher the underlying pathways by which they cause disease, and develop preventive measures and treatments for many of the world's most dangerous pathogens has resulted in considerable progress. Intramural and extramural investigators supported by the National Institute of Allergy and Infectious Diseases (NIAID) have contributed substantially to this effort. This overview highlights selected NIAID-sponsored research advances over the past decade, with a focus on progress in combating HIV/AIDS, malaria, tuberculosis, influenza, SARS, West Nile virus, and potential bioterror agents. Many basic research discoveries have been translated into novel diagnostics, antiviral and antimicrobial compounds, and vaccines, often with extraordinary speed.
-
the challenge of emerging and re emerging Infectious Diseases
Nature, 2004Co-Authors: David M. Morens, Gregory K. Folkers, Anthony S FauciAbstract:Infectious Diseases have for centuries ranked with wars and famine as major challenges to human progress and survival. They remain among the leading causes of death and disability worldwide. Against a constant background of established infections, epidemics of new and old Infectious Diseases periodically emerge, greatly magnifying the global burden of infections. Studies of these emerging infections reveal the evolutionary properties of pathogenic microorganisms and the dynamic relationships between microorganisms, their hosts and the environment.
-
Infectious Diseases considerations for the 21st century
Clinical Infectious Diseases, 2001Co-Authors: Anthony S FauciAbstract:The discipline of Infectious Diseases will assume added prominence in the 21st century in both developed and developing nations. To an unprecedented extent, issues related to Infectious Diseases in the context of global health are on the agendas of world leaders, health policymakers, and philanthropies. This attention has focused both on scientific challenges such as vaccine development and on the deleterious effects of Infectious Diseases on economic development and political stability. Interest in global health has led to increasing levels of financial support, which, combined with recent technological advances, provide extraordinary opportunities for Infectious disease research in the 21st century. The sequencing of human and microbial genomes and advances in functional genomics will underpin significant progress in many areas, including understanding human predisposition and susceptibility to disease, microbial pathogenesis, and the development new diagnostics, vaccines, and therapies. Increasingly, Infectious disease research will be linked to the development of the medical infrastructure and training needed in developing countries to translate scientific advances into operational reality.
Michael Greger - One of the best experts on this subject based on the ideXlab platform.
-
the human animal interface emergence and resurgence of zoonotic Infectious Diseases
Critical Reviews in Microbiology, 2007Co-Authors: Michael GregerAbstract:Emerging Infectious Diseases, most of which are considered zoonotic in origin, continue to exact a significant toll on society. The origins of major human Infectious Diseases are reviewed and the factors underlying disease emergence explored. Anthropogenic changes, largely in land use and agriculture, are implicated in the apparent increased frequency of emergence and re-emergence of zoonoses in recent decades. Special emphasis is placed on the pathogen with likely the greatest zoonotic potential, influenzavirus A.
-
the human animal interface emergence and resurgence of zoonotic Infectious Diseases
Critical Reviews in Microbiology, 2007Co-Authors: Michael GregerAbstract:Emerging Infectious Diseases, most of which are considered zoonotic in origin, continue to exact a significant toll on society. The origins of major human Infectious Diseases are reviewed and the factors underlying disease emergence explored. Anthropogenic changes, largely in land use and agriculture, are implicated in the apparent increased frequency of emergence and re-emergence of zoonoses in recent decades. Special emphasis is placed on the pathogen with likely the greatest zoonotic potential, influenzavirus A.
Yaohe Wang - One of the best experts on this subject based on the ideXlab platform.
-
syrian hamster as an animal model for the study on Infectious Diseases
Frontiers in Immunology, 2019Co-Authors: Ls Chard, Jinxin Miao, Zhimin Wang, Yaohe WangAbstract:Infectious Diseases still remain one of the biggest challenges for human health. In order to gain a better understanding of the pathogenesis of Infectious Diseases and develop effective diagnostic tools, therapeutic agents, and preventive vaccines, a suitable animal model which can represent the characteristics of Infectious is required. The Syrian hamster immune responses to Infectious pathogens are similar to humans and as such, this model is advantageous for studying pathogenesis of infection including post-bacterial, viral and parasitic pathogens, along with assessing the efficacy and interactions of medications and vaccines for those pathogens. This review summarizes the current status of Syrian hamster models and their use for understanding the underlying mechanisms of pathogen infection, in addition to their use as a drug discovery platform and provides a strong rationale for the selection of Syrian hamster as animal models in biomedical research. The challenges of using Syrian hamster as an alternative animal model for the research of Infectious Diseases are also addressed.
Catherine Liu - One of the best experts on this subject based on the ideXlab platform.
-
therapeutic monitoring of vancomycin for serious methicillin resistant staphylococcus aureus infections a revised consensus guideline and review by the american society of health system pharmacists the Infectious Diseases society of america the pediatric Infectious Diseases society and the society of Infectious Diseases pharmacists
Clinical Infectious Diseases, 2020Co-Authors: John S Bradley, Michael J Rybak, Thomas P Lodise, Donald P Levine, Catherine LiuAbstract:Recent clinical data on vancomycin pharmacokinetics and pharmacodynamics suggest a reevaluation of current dosing and monitoring recommendations. The previous 2009 vancomycin consensus guidelines recommend trough monitoring as a surrogate marker for the target area under the curve over 24 hours to minimum inhibitory concentration (AUC/MIC). However, recent data suggest that trough monitoring is associated with higher nephrotoxicity. This document is an executive summary of the new vancomycin consensus guidelines for vancomycin dosing and monitoring. It was developed by the American Society of Health-System Pharmacists, the Infectious Diseases Society of America, the Pediatric Infectious Diseases Society, and the Society of Infectious Diseases Pharmacists vancomycin consensus guidelines committee. These consensus guidelines recommend an AUC/MIC ratio of 400-600 mg*hour/L (assuming a broth microdilution MIC of 1 mg/L) to achieve clinical efficacy and ensure safety for patients being treated for serious methicillin-resistant Staphylococcus aureus infections.
